GlassScriptPhysician profile
Kimberly A Huffman
NPI 1083664270
$2,546.16
in general payments reported to CMS, 2019-2025
29 companies · $397 in 2025
The $397 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $230 · 2021: $241 · 2022: $503 · 2023: $321 · 2024: $377 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,094.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $614.46 | 2019-2025 | |
| Astellas Pharma US INC | $365.28 | 2019-2025 | Veozah |
| Mayne Pharma Commercial LLC | $299.24 | 2022-2025 | |
| Evofem Biosciences, INC. | $218.85 | 2022-2025 | Phexxi, Solosec, Phexx |
| Pfizer INC. | $184.81 | 2020-2024 | |
| Coopersurgical, INC. | $82.84 | 2019-2024 | Paragard T 380a, Wallach Cryosurgical Equipment |
| Myovant Sciences INC. | $80.72 | 2022 | |
| Sumitomo Pharma America, INC. | $68.50 | 2025 | Myfembree |
| Exeltis, USA INC. | $62.63 | 2020-2024 | Slynd |
| Avion Pharmaceuticals | $59.40 | 2019-2022 | |
| Revance Therapeutics, INC. | $55.56 | 2024 | Daxxify |
| Bayer Healthcare Pharmaceuticals INC. | $39.86 | 2019-2023 | |
| Millicent US INC | $38.70 | 2024-2025 | Femlyv, Intrarosa |
| Alydia Health | $37.90 | 2021 | |
| Optumhealth Care Solutions, LLC | $35.87 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $35.66 | 2019 | |
| Roche Diagnostics Corporation | $29.27 | 2019 | |
| Allergan, INC. | $29.04 | 2019-2020 | |
| Inari Medical, INC. | $28.35 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Tersera Therapeutics LLC | $27.26 | 2025 | Quzyttir |
| Shield Therapeutics INC | $23.40 | 2022 | |
| Meditrina | $19.47 | 2023 | |
| Hologic Sales and Service, LLC | $19.16 | 2025 | Myosure Tissue Removal Device, Novasure |
| Boston Scientific Corporation | $16.41 | 2022 | |
| Organon LLC | $16.22 | 2024 | |
| Daiichi Sankyo INC. | $15.73 | 2020 | |
| Amag Pharmaceuticals, INC. | $14.64 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.04 | 2019 | |
| Novo Nordisk INC | $12.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Huffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.